KURE vs MCHI
KraneShares MSCI All China Health Care Index ETF against iShares MSCI China ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
5%
40 shared positions
Fee gap
6 bp
MCHI is cheaper
1-year return gap
7.9 pts
KURE is ahead
Larger fund
MCHI
$6.0B
Side by side
| KURE | MCHI | |
|---|---|---|
| Fund | KraneShares MSCI All China Health Care Index ETF | iShares MSCI China ETF |
| Issuer | KraneShares | iShares |
| Category | Single Country | Single Country |
| Expense ratio | 0.65% | 0.59% |
| Assets | $110M | $6.0B |
| Average daily dollar volume | $1.5M | $92M |
| Listed | Jan 31, 2018 | Mar 29, 2011 |
| FrenzyCap score | 38 | 70 |
| 1-month return | +5.2% | −0.5% |
| 3-month return | +11.0% | +0.0% |
| Year to date | +9.9% | −12.5% |
| 1-year return | −12.6% | −20.5% |
| 30-day volatility | 29.4% | 17.0% |
| Worst drawdown, 1 year | −29.7% | −23.0% |
| Trailing 12-month yield | 3.82% | 2.09% |
| Holdings | 63 | 586 |
| Top 10 weight | 53.9% | 41.1% |
| Look-through P/E | — | — |
| Holdings vs fair value | — | — |
| Holdings above 200-day average | — | — |
| Net flow, latest 3 reported months | −$3.3M thru Jun 2026 | −$625M thru May 2026 |
| 30-day implied volatility | 51.2% | 20.1% |
| Holdings as of | as of Jun 30, 2026SEC filing | as of Oct 8, 2026issuer data |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
88% of KURE · 5% of MCHI| Holding | KURE | MCHI |
|---|---|---|
| WUXI BIOLOGICS (CAYMAN) INC. | 7.51% | 1.02% |
| INNOVENT BIOLOGICS, INC. | 8.80% | 0.71% |
| WuXi AppTec Co., Ltd. | 3.35% | 0.44% |
| CSPC PHARMACEUTICAL GROUP LIMITED | 3.68% | 0.40% |
| Akeso Inc | 3.72% | 0.37% |
| SINO BIOPHARMACEUTICAL LIMITED | 3.38% | 0.29% |
| Genscript Biotech Corp | 1.11% | 0.26% |
| HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED | 2.85% | 0.21% |
| WuXi XDC Cayman Inc | 1.35% | 0.17% |
| 3SBio Inc. | 2.49% | 0.15% |
| WuXi AppTec Co., Ltd. | 5.79% | 0.15% |
| Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 1.85% | 0.15% |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 4.59% | 0.11% |
| XtalPi Holdings Limited | 1.00% | 0.11% |
| SINOPHARM GROUP CO. LTD. | 1.67% | 0.11% |
| Shenzhen Mindray Bio-Medical Electronics Co Ltd | 4.28% | 0.07% |
| RemeGen Co Ltd | 1.05% | 0.07% |
| LEGN | 1.28% | 0.06% |
| Shanghai United Imaging Healthcare Co., Ltd. | 2.27% | 0.03% |
| YUNNAN BAIYAO GROUP CO., LTD | 2.31% | 0.03% |
| Aier Eye Hospital Group Co., Ltd. | 2.10% | 0.03% |
| ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD. | 1.81% | 0.03% |
| Pharmaron Beijing Co., Ltd. | 1.15% | 0.03% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 1.61% | 0.02% |
| Sichuan Biokin Pharmaceutical Co Ltd | 1.97% | 0.02% |
Sector mix of the stock holdings
| Sector | KURE | MCHI | Gap |
|---|---|---|---|
| Industrials | 0.0% | 1.7% | −1.7% |
| Health Care | 1.3% | 0.1% | +1.2% |
| Consumer Discretionary | 0.0% | 0.6% | −0.6% |
| Technology | 0.0% | 0.5% | −0.5% |
| Communication Services | 0.0% | 0.2% | −0.2% |
More: full overlap table · KURE holdings · MCHI holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.